Medical Condition News

RSS

Research findings could offer new approach to diabetes therapy, nutrition experts say

Nutrition experts at Oregon State University have essentially "cured" laboratory mice of mild, diet-induced diabetes by stimulating the production of a particular enzyme. The findings could offer a new approach to diabetes therapy, experts say, especially if a drug could be identified that would do the same thing, which in this case was accomplished with genetic manipulation.

13 Jul 2010

Obesity crisis in the spotlight as FDA reviews weight loss drugs

The Washington Post explores the obesity epidemic by reporting from Manchester, Ky., which has an obesity rate as high as 52 percent in a nation where the obesity rate is 24 percent. "The residents of this town of 2,100 — 95 miles southeast of Lexington and deep in the Appalachian foothills — indeed appear to celebrate the joys of community closeness.

13 Jul 2010

Study explores direct role of FTO gene on Alzheimer's and dementia risk in old age

A gene known as FTO, which appears to be correlated with obesity in humans, may also increase risk of Alzheimer's disease and dementia, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI. And when a person has certain variants of both FTO and a recognized Alzheimer's risk gene known as APOE, the risk of Alzheimer's could be doubled.

13 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Bedford Laboratories launches Dactinomycin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.

12 Jul 2010

Scientists discover way to enhance nerve regeneration in peripheral nervous system

Faculty of Medicine scientists have discovered a way to enhance nerve regeneration in the peripheral nervous system. This important discovery could lead to new treatments for nerve damage caused by diabetes or traumatic injuries. Peripheral nerves connect the brain and spinal cord to the body, and without them, there is no movement or sensation. Peripheral nerve damage is common and often irreversible. This discovery is published in the July 7, 2010 edition of the Journal of Neuroscience.

12 Jul 2010

Tips on skin care

Your skin protects you, heals itself and lasts a lifetime. Find how to give it some skin care in return, to help keep it looking and feeling its best.

12 Jul 2010

BSD receives FDA review questions for Phase II MTX-180 Microwave Ablation System 510(k) submission

BSD Medical Corporation today announced that it has received review questions from the U.S. Food and Drug Administration (FDA) regarding the 510(k) submission the Company filed for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System (MTX-180) for ablation of soft tissue.

12 Jul 2010

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

GE Healthcare Medical Diagnostics today announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.

12 Jul 2010

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.

12 Jul 2010

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Biodel Inc. announced today the award of two research grants by the Juvenile Diabetes Research Foundation to Stanford University and Oregon Health & Science University to evaluate the use of VIAject (ultra-rapid-acting injectable human insulin) in the treatment of diabetes.

12 Jul 2010

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Reata Pharmaceuticals, Inc. has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.

12 Jul 2010

Study results show cognitive decline significantly lower among regular tea drinkers

Results of a new study found people age 65 or older who drank tea regularly had 17-37% less cognitive decline compared with people who did not drink tea. The new findings were presented here at the Alzheimer's Association's International Conference on Alzheimer's Disease 2010.

12 Jul 2010

Bayer HealthCare announces over $2.5M for largest awards program in hemophilia

Bayer HealthCare announced today that it awarded more than $2.5 million in funding to 19 recipients from 10 countries through its Bayer Hemophilia Awards Program (BHAP). BHAP is the largest awards program of its kind in hemophilia, providing funds that support clinical and basic research, encourage new physicians to enter the field and enable continuing education for caregivers around the world.

12 Jul 2010

Researchers investigate impact of flavonols on stroke risk

New research has found that people who consume relatively high amounts of flavonols have a lower risk of stroke. Tea was most likely the major contributor of flavonols in the diet, ranging from 30 percent (US) to 70 percent (the Netherlands) of the total intake.

12 Jul 2010

Survey shows only few Canadians identify painful physical symptoms of depression

Although the majority of Canadians believe in a mind/body connection, agreeing how they feel physically is related to how they feel emotionally (87 per cent), only half make the link when it comes to depression.

12 Jul 2010

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases. The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD), and pulmonary embolism, independent of other known risk factors.

12 Jul 2010

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.

12 Jul 2010

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

AngioDynamics announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex® port technology - to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT).

12 Jul 2010

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

12 Jul 2010

Medical Condition News

Research findings could offer new approach to diabetes therapy, nutrition experts say

Obesity crisis in the spotlight as FDA reviews weight loss drugs

Study explores direct role of FTO gene on Alzheimer's and dementia risk in old age

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Bedford Laboratories launches Dactinomycin for Injection

Scientists discover way to enhance nerve regeneration in peripheral nervous system

Tips on skin care

BSD receives FDA review questions for Phase II MTX-180 Microwave Ablation System 510(k) submission

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Study results show cognitive decline significantly lower among regular tea drinkers

Bayer HealthCare announces over $2.5M for largest awards program in hemophilia

Researchers investigate impact of flavonols on stroke risk

Survey shows only few Canadians identify painful physical symptoms of depression

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News